ПРИМЕНЕНИЕ БОЗУТИНИБА ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ С ХРОНИЧЕСКИМ МИЕЛОЛЕЙКОЗОМ И ЕГО ВЛИЯНИЕ НА СЕРДЕЧНО-СОСУДИСТУЮ СИСТЕМУ (ЛИТЕРАТУРНЫЙ ОБЗОР)

Библиографические ссылки:

Bower H., Björkholm M., Dickman P.W. et al. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J ClinOncol. 2016 Aug 20; 34(24): 2851-7. doi: 10.1200/JCO.2015.66.2866.

Brümmendorf T.H., Cortes J.E., Milojkovic D. et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022; 36: 1825–1833.https://doi.org/10.1038/s41375-022-01589-y

Brümmendorf T.H., Cortes J.E., de Souza C.A. et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015 Jan; 168(1): 69-81. doi: 10.1111/bjh.13108.

Caocci G., Mulas O., Bonifacio M. et al. Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. Int J Cardiol. 2019 Aug 1; 288: 124-127. doi: 10.1016/j.ijcard.2019.04.051.

Chen K.-K., Du T.-F. et al. First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis. Cancer Management and Research. 2018; Volume 10: 3891–3910. doi:10.2147/cmar.s177566

Chen M.T., Huang S.T., Lin C.W. et al. Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based, Propensity Score-Matched Cohort Study. Oncologist. 2021 Nov; 26(11): 974-982. doi: 10.1002/onco.13944.

Cortes J.E., Jean Khoury H., Kantarjian H. et al. Longterm evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol. 2016; 91: 606–616.

Deb S., Boknäs N., Sjöström C. et al. (2019). Varying effects of tyrosine kinase inhibitors on platelet function—A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications? Cancer Medicine. doi:10.1002/cam4.2687

Eskazan A.E., Ozmen D. Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events – is better always good? Expert Review of Hematology. 2017; 10(7): 583–586. doi:10.1080/17474086.2017.1339599

Fachi M.M., Tonin F.S., Leonart L.P. et al. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis. European Journal of Cancer. 2018; 104: 9–20. doi:10.1016/j.ejca.2018.08.016

Fachi M.M., Tonin F.S., Leonart L.P. et al. Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis. Br J Clin Pharmacol. 2019 Oct; 85(10): 2280-2291. doi: 10.1111/bcp.13933.

Galanis A., Levis M. Inhibition of c-Kit by tyrosine kinase inhibitors. Haematologica. 2015 Mar; 100(3): e77-9. doi: 10.3324/haematol.2014.117028.

Gambacorti-Passerini C., Cortes J.E., Lipton J.H. et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014 Oct; 89(10): 947-53. doi: 10.1002/ajh.23788.

Gover-Proaktor A., Granot G., Pasmanik-Chor M. et al. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells. Leukemia & Lymphoma. 2018; 1–11. doi:10.1080/10428194.2018.1466294

Gover-Proaktor A., Granot G., Shapira S. et al. Ponatinib reduces viability, migration, and functionality of human endothelial cells. Leuk Lymphoma. 2017; 58: 1455–1467.

Gustafson D., Fish J.E., Lipton J.H. et al. Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia. CurrHematolMalig. 2020; Rep 15: 20–30.https://doi.org/10.1007/s11899-020-00560-x

Haguet H., Bouvy C., Delvigne AS. et al. (2020). The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study. Frontiers in Pharmacology, 11. doi:10.3389/fphar.2020.01007

Haguet H., Douxfils J., Chatelain C. et al. Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis? TH Open. 2018 Feb 14; 2(1): e68-e88. doi: 10.1055/s-0038-1624566.

Haguet H., Douxfils J., Mullier F. et al. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf. 2017 Jan; 16(1): 5-12. doi: 10.1080/14740338.2017.1261824.

KhaddajMallat R., Mathew John C., Kendrick D.J. et al. The vascular endothelium: A regulator of arterial tone and interface for the immune system. Critical Reviews in Clinical Laboratory Sciences. 2017; 54(7-8), 458–470. doi:10.1080/10408363.2017.1394267

Kirkizlar O., Eskazan A. Adverse events of tyrosine kinase inhibitors and their impact on quality of life in patients with chronic myeloid leukemia. Expert Review of Quality of Life in Cancer Care. 2016; 1(5): 353–359. doi:10.1080/23809000.2016.1214058

Ma Y., Liu X., Bi Y. et al. Alteration of N6-Methyladenosine mRNA Methylation in a Human Stem Cell-Derived Cardiomyocyte Model of Tyrosine Kinase Inhibitor-Induced Cardiotoxicity. Front Cardiovasc Med. 2022 Mar 23; 9: 849175. doi: 10.3389/fcvm.2022.849175.

Medeiros B.C., Possick J., Fradley M. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. Blood Rev. 2018 Jul; 32(4): 289-299. doi: 10.1016/j.blre.2018.01.004.

Mulas O., Caocci G., Mola B. et al. Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021 Sep 22; 12: 674748. doi: 10.3389/fphar.2021.674748.

Ota S., Matsukawa T., Yamamoto S. et al. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Eur J Haematol. 2018 Jul; 101(1): 95-105. doi: 10.1111/ejh.13081.

Pan P., Wang L., Wang Y. et al. Systematic Review and Meta-Analysis of New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. Acta Haematologica. 2019; 1–13. doi: 10.1159/000501537

Piepoli M.F., Hoes A.W., Agewall S. et al. 2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Eur. Heart J. 2016; 37(29), 2315–2381. doi: 10.1093/eurheartj/ehw106

Saydam G., Ali R., Demir A.M. et al. The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Int J HematolOncol. 2022 May 24; 11(1): IJH38. doi: 10.2217/ijh-2021-0010.

Valent P., Hadzijusufovic E., Hoermann G. et al. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leuk Res. 2017; 59: 47–54.